A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model.

Experimental & Translational Stroke Medicine Pub Date : 2014-10-09 eCollection Date: 2014-01-01 DOI:10.1186/2040-7378-6-10
Md Nasrul Hoda, Susan C Fagan, Mohammad B Khan, Kumar Vaibhav, Aizaz Chaudhary, Phillip Wang, Krishnan M Dhandapani, Jennifer L Waller, David C Hess
{"title":"A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model.","authors":"Md Nasrul Hoda,&nbsp;Susan C Fagan,&nbsp;Mohammad B Khan,&nbsp;Kumar Vaibhav,&nbsp;Aizaz Chaudhary,&nbsp;Phillip Wang,&nbsp;Krishnan M Dhandapani,&nbsp;Jennifer L Waller,&nbsp;David C Hess","doi":"10.1186/2040-7378-6-10","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>After the failure of so many drugs and therapies for acute ischemic stroke, innovative approaches are needed to develop new treatments. One promising strategy is to test combinations of agents in the pre-hospital setting prior to the administration of intravenous tissue plasminogen activator (IV-tPA) and/ or the use of mechanical reperfusion devices in the hospital.</p><p><strong>Methods: </strong>We performed a 2 × 2 factorial design preclinical trial where we tested minocycline (MINO), remote ischemic perconditioning (RIPerC) and their combination treatment in a thromboembolic clot model of stroke in mice, without IV-tPA or later treated with IV-tPA at 4 hours post-stroke. Cerebral blood flow (CBF) was measured by laser speckle contrast imaging (LSCI), behavioral outcomes as neurological deficit score (NDS) and adhesive tape removal test, and infarct size measurement were performed at 48 hours post-stroke. Mice within the experimental sets were randomized for the different treatments, and all outcome measures were blinded.</p><p><strong>Results: </strong>RIPerC significantly improved CBF as measured by LSCI in both with and without tPA treated mice (P < 0.001). MINO and RIPerC treatment were effective alone at reducing infarct size (p < 0.0001) and improving short-term functional outcomes (p < 0.001) in the tPA and non-tPA treated animals. The combination treatment of MINO and RIPerC significantly reduced the infarct size greater than either intervention alone (p < 0.05). There were trends in favor of improving functional outcomes after combination treatment of MINO and RIPerC; however combination treatment group was not significantly different than the individual treatments of MINO and RIPerC. There was no \"statistical\" interaction between minocycline and RIPerC treatments indicating that the effects of RIPerC and MINO were additive and not synergistic on the outcome measures.</p><p><strong>Conclusion: </strong>In the future, combining these two safe and low cost interventions in the ambulance has the potential to \"freeze\" the penumbra and improve outcomes in stroke patients. This pre-clinical 2 × 2 design can be easily translated into a pre-hospital clinical trial.</p>","PeriodicalId":12158,"journal":{"name":"Experimental & Translational Stroke Medicine","volume":"6 ","pages":"10"},"PeriodicalIF":0.0000,"publicationDate":"2014-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/2040-7378-6-10","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental & Translational Stroke Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/2040-7378-6-10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 27

Abstract

Background: After the failure of so many drugs and therapies for acute ischemic stroke, innovative approaches are needed to develop new treatments. One promising strategy is to test combinations of agents in the pre-hospital setting prior to the administration of intravenous tissue plasminogen activator (IV-tPA) and/ or the use of mechanical reperfusion devices in the hospital.

Methods: We performed a 2 × 2 factorial design preclinical trial where we tested minocycline (MINO), remote ischemic perconditioning (RIPerC) and their combination treatment in a thromboembolic clot model of stroke in mice, without IV-tPA or later treated with IV-tPA at 4 hours post-stroke. Cerebral blood flow (CBF) was measured by laser speckle contrast imaging (LSCI), behavioral outcomes as neurological deficit score (NDS) and adhesive tape removal test, and infarct size measurement were performed at 48 hours post-stroke. Mice within the experimental sets were randomized for the different treatments, and all outcome measures were blinded.

Results: RIPerC significantly improved CBF as measured by LSCI in both with and without tPA treated mice (P < 0.001). MINO and RIPerC treatment were effective alone at reducing infarct size (p < 0.0001) and improving short-term functional outcomes (p < 0.001) in the tPA and non-tPA treated animals. The combination treatment of MINO and RIPerC significantly reduced the infarct size greater than either intervention alone (p < 0.05). There were trends in favor of improving functional outcomes after combination treatment of MINO and RIPerC; however combination treatment group was not significantly different than the individual treatments of MINO and RIPerC. There was no "statistical" interaction between minocycline and RIPerC treatments indicating that the effects of RIPerC and MINO were additive and not synergistic on the outcome measures.

Conclusion: In the future, combining these two safe and low cost interventions in the ambulance has the potential to "freeze" the penumbra and improve outcomes in stroke patients. This pre-clinical 2 × 2 design can be easily translated into a pre-hospital clinical trial.

Abstract Image

Abstract Image

Abstract Image

二甲胺四环素和远端缺血过适应联合治疗的2 × 2因子设计:小鼠血栓栓塞性卒中模型临床前试验的疗效。
背景:在治疗急性缺血性卒中的许多药物和疗法失败后,需要创新的方法来开发新的治疗方法。一种有前景的策略是在院前静脉注射组织型纤溶酶原激活剂(IV-tPA)和/或在医院使用机械再灌注装置之前测试药物组合。方法:我们进行了一项2 × 2因子设计的临床前试验,在脑卒中小鼠血栓栓塞性凝块模型中测试二甲胺四环素(MINO)、远端缺血过适应(RIPerC)及其联合治疗,在脑卒中后4小时不使用IV-tPA或随后使用IV-tPA治疗。脑卒中后48小时,采用激光散斑造影(LSCI)测量脑血流量(CBF)、神经功能缺损评分(NDS)和胶带去除测试等行为结果,并测量梗死面积。实验组内的小鼠被随机分配到不同的治疗组,所有的结果测量都是盲法的。结论:在未来,在救护车中结合这两种安全且低成本的干预措施有可能“冻结”半暗带并改善中风患者的预后。这种临床前2 × 2设计可以很容易地转化为院前临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信